Results 251 to 260 of about 606,093 (296)
Advances in meningococcal vaccines
Clinical Practice, 2012 SUMMARY During the 20th century, meningococcal vaccine manufacturers took advantage of conjugate technology to provide products that could protect infants, the most vulnerable population, against invasive disease caused by serogroup C.
M. Pizza, L. DeTora, J. Wassil
semanticscholar +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Infectious Diseases, 2020
BACKGROUND Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N.
M. McMillan +7 more
semanticscholar +1 more source
BACKGROUND Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N.
M. McMillan +7 more
semanticscholar +1 more source
Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein +2 more
openaire +2 more sources
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein +2 more
openaire +2 more sources
[Experts' consensus on immunization with meningococcal vaccines in China].
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2019Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine, meningococcal polysaccharide conjugate vaccine, and a combined vaccine.
semanticscholar +1 more source
Meningococcal conjugate vaccines
Expert Opinion on Pharmacotherapy, 2004Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire +3 more sources
Bioanalysis of Meningococcal Vaccines
Bioanalysis, 2010Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Jun X. Wheeler +2 more
openaire +3 more sources
MMWR. Morbidity and mortality weekly report, 2015
At its June 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and young adults aged 16–23 years may be vaccinated with a serogroup B meningococcal (MenB) vaccine to provide short-term protection against ...
Jessica R Macneil +5 more
semanticscholar +1 more source
At its June 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and young adults aged 16–23 years may be vaccinated with a serogroup B meningococcal (MenB) vaccine to provide short-term protection against ...
Jessica R Macneil +5 more
semanticscholar +1 more source
Current Pharmaceutical Design, 2007
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Meningococcal carriage, meningococcal disease and vaccination
Journal of Infection, 1988Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
R.A. Wall +2 more
openaire +3 more sources
The Future of Meningococcal Vaccines
Pediatric Infectious Disease Journal, 2005Despite antibiotics and supportive care ~10% of persons with meningococcal infection die 9-19% have sequelae (skin grafting amputation hearing deficits) and outbreaks often provoke panic. Meningococcal meningitis is the main cause of bacterial meningitis in children in the United States.
Carol J. Baker, C. Mary Healy
openaire +3 more sources